Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk over alleged GLP-1 weight loss drug competition limits. Read more ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

The health care industry has never encountered anything quite like Ozempic before. First approved to treat Type 2 diabetes, this drug and others like it—known as GLP-1 agonists—hit blockbuster status ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss therapy Wegovy (semaglutide), Hims & Hers Health CEO Andrew Dudum said that ...

Discover how compounding pharmacies are transforming healthcare by creating tailor-made medications for patients with unique needs, offering critical alternatives when standard drugs fall short, and ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding ...

Glucagon-like peptide-1, or “GLP-1” drugs, such as Ozempic® and Mounjaro®, have exploded in popularity in the United States for weight management and the treatment of obesity. However, GLP-1 drugs ...

Does compounded Semaglutide work for weight loss? Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But it’s important to understand ...